Ruxolitinib is more effective than other JAK inhibitors to treat VEXAS syndrome: a retrospective multicenter study
Maël Heiblig(Université Claude Bernard Lyon 1), Pierre Sujobert(Université Claude Bernard Lyon 1)
Cited by 201
Related Papers
Further characterization of clinical and laboratory features in VEXAS syndrome: large‐scale analysis of a multicentre case series of 116 French patients*
|British Journal of Dermatology|2021|414
Serious infections in patients with VEXAS syndrome: data from the French VEXAS registry
|Annals of the Rheumatic Diseases|2023|70